Malignant melanoma of eye Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Malignant melanoma of eye. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Malignant melanoma of eye receives a directional score of 57/100, combining unmet need (68/100), competitive intensity (96/100) and market attractiveness (83/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A melanoma that arises from the structures of the eye.

The reproducible record is Patsnap disease ID 48f7b774514d4587ae812ff12a86e872. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Recent global patterns in skin cancer incidence, mortality, and prevalence

Results from several epidemiological studies have indicated that the incidence of skin cancer has been increasing over time. The prevalence of both non-melanoma and mel- anoma skin cancers varies widely across the globe, with the highest prevalence in Australia and the lowest in parts of Africa.[14–17] Recent epidemiological findings project that there will be 96,000 new melanoma cases in 2040 based on the incidence rates of 51,000 mela noma cases in 2020. Such increases will exert a huge disease burden in fair-skinned people of European descent.[13] In addition, non-melanoma skin cancer poses a significant global healthcare burden as well, with studies showing that this condition represents the fifth highest healthcare costs in Australia, America, and Europe (after prostate, lung, colon, and breast cancers).[18,19] In addition, the significant age differences in the incidence of melanoma are also a matter of some concern. An observational study based on the National Program of Cancer Registries-Surveillance Epide- miology and End Results United States Cancer Statistics database found that, while the incidence of melanoma in the United States, as well as in central Canada, has declined within adolescents and young adults, this downward trend is not as pronounced among Hispanics and young children and has actually increased in older populations.[20–22] Interestingly, the gender differences in melanoma incidence are associated with specific anatomical sites, with males showing increased prevalence in the head, neck, and trunk and females in the lower limbs and buttocks. This

Review source

Epidemiology evidence 2: Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results Incidence and prognosis of cutaneous melanoma in European adolescentsand young adults (AYAs): EUROCARE-6 retrospective cohort results

We estimated variation in melanoma IR in the period 2000–2013 using incidence rate ratios (IRRs, i.e., the ratio between the IR in 2009–2013 and in 2000–2004). We analyzed changes in 5-year RS, using the difference in survival between two follow-up periods: 2010–2014 (cohort diagnosed 2006–2013) and 2004–2006 (cohort diagnosed 2000–2006). We used the z-test to assess relevant survival differences over time and the F-Intervals p-value [10] to evaluate IRR differences over time. Of the 95 CRs contributing data, 69 provided data covering at least the period of diagnosis 2001–2010, which contributed to the survival and incidence trend analyses. 3. Results We analyzed 48,000 AYA with CM in 2006–2013. The IR of CM in AYA was 6.9 per 100,000, proving to be higher in females than in males (Table 1). Considering all age groups, the IR of CM was found to increase with age, ranging from 0.43 for 0–19 year-olds to 47.04 for those aged ≥ 70 (Table 1). However, CM corresponds to 10 % of all malignant AYA cancers. The IR of CM differed between males and females with age. The IR of CM was higher in females than in males among younger people (0–19 year-olds) and young adults (20–39 year- olds), was almost the same for older male and female adults (40–69 year-olds), and was higher in elderly males (≥70 years) (Table 1). In AYAs, primary mucosal, brain, and eye melanoma IRs were < 01/100,000. (Data available from the corresponding author). Table 2 reports the IRs of CM by site at onset, age, and sex. Females Cutaneous melanoma incidence rate (IR) in European adolescents and young adults (aged

Review source

Epidemiology evidence 3: Global Cancer Statistics, 2002

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Age-standardized Incidence Rates for Melanoma. * Chart Type: Bar Chart (specifically, a horizontal grouped bar chart displaying male and female incidence rates side-by-side for each region). * Contextual Summary: The chart presents the age-standardized incidence rates of melanoma per 100,000 population, broken down by geographical region and sex, to illustrate variations in disease frequency worldwide. 2. Chart Structure and Elements * Axes/Headers: * X-Axis: Age standardized incidence per 100,000 * Y-Axis: Geographical regions * Legend/Groups: * Blue bars represent incidence rates for Males. * Pink bars represent incidence rates for Females. * Notes and Footnotes: * "Data shown per 100,000 by sex." (This note appears in the text following the chart and refers to Figure 16, which is this chart.) 3. Detailed Data Transcription This chart displays the age-standardized incidence rates of melanoma per 100,000 individuals, categorized by geographical region and sex. The data is presented with male incidence rates (blue bars) extending left from the central axis and female incidence rates (pink bars) extending right. * Australia/New Zealand: * Males: 37.7 per 100,000 * Females: 29.4 per 100,000 * Northern America: * Males: 16.4 per 100,000 * Females: 11.7 per 100,000 * Northern Europe: * Males: 8.4 per 100,000 * Females: 10.0 per 100,000 * Western Europe: * Males: 7.3 per 100,000 * Females: 10.3 per 100,000 * Southern Europe: * Males: 6.0 per 100,000 * Females: 5.5 per 100,000 * Southern Africa: * Males

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Malignant melanoma of eye, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Malignant melanoma of eye thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: RPE65

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore (PubMed:16116091). Essential for the production of 11-cis retinal for both rod and cone photoreceptors (PubMed:17848510). Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid (PubMed:28874556). The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity).

The mechanism anchor is RPE65, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 408 registered studies.

• NCT07747935 — Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma (Uveal Melanoma); Not yet recruiting; Phase 1/2; sponsor Rebio Pharma; enrollment 30.
• ChiCTR2600128986 — Practical Approach to Emergency Care for Air Embolism Complicating Surgery in a Patient with Choroidal Melanoma; Not yet recruiting; Not Applicable; sponsor The First Affiliated Hospital of Nanchang University; enrollment 4.
• JPRN-UMIN000062039 — Development of Beam Imaging Technology for Scanning Irradiation in Heavy Ion Radiotherapy; 一般募集中/Open public recruiting; Not Applicable; sponsor National Institutes For Quantum Science &Technology; enrollment 5.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 1 directly matched 2023–2026 transactions.

• Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor (2024-08-15). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate RPE65 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Malignant melanoma of eye merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Malignant melanoma of eye is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.